Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OncoVEX GM-CSF vs GM-CSF in unresectable melanoma
2008-006140-20Phase 3Completed
- Sponsor
- BioVex Group, Inc.
- Start
- Apr 2009
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of talimogene laherparepvec in melanoma (2 arms), sponsored by BioVex Group, Inc. Primary endpoints: Objective response rate maintained for a defined duration and Safety. Started Apr 2009; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on 2008-006140-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006140-20.